Neuroprotective effects of the drug GVT (monosodium luminol) are mediated by the stabilization of Nrf2 in astrocytes
- 30 June 2010
- journal article
- Published by Elsevier in Neurochemistry International
- Vol. 56 (6-7) , 780-788
- https://doi.org/10.1016/j.neuint.2010.02.017
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's diseaseProceedings of the National Academy of Sciences, 2009
- Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in miceBrain Research, 2009
- Oxidative Stress Is Linked to ERK1/2-p16 Signaling-mediated Growth Defect in ATM-deficient AstrocytesJournal of Biological Chemistry, 2009
- Bioluminescence imaging of myeloperoxidase activity in vivoNature Medicine, 2009
- The Nrf2/ARE Pathway as a Potential Therapeutic Target in Neurodegenerative DiseaseAntioxidants and Redox Signaling, 2009
- Antiviral Activity of Nrf2 in a Murine Model of Respiratory Syncytial Virus DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- The Nrf2–ARE PathwayAnnals of the New York Academy of Sciences, 2008
- DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2Proceedings of the National Academy of Sciences, 2006
- Retrovirus-Induced Oxidative Stress with Neuroimmunodegeneration Is Suppressed by Antioxidant Treatment with a Refined Monosodium α-Luminol (Galavit)Journal of Virology, 2006
- Oxidative damage in Alzheimer'sNature, 1996